Fierce Pharma
JUNE 27, 2024
Years of negotiations and legal proceedings surrounding a high-dollar opioid settlement for Purdue Pharma have reached a dead end at the U.S. Supreme Court. | Years of negotiations and legal proceedings surrounding a high-dollar opioid settlement for Purdue Pharma have reached a dead end at the U.S. Supreme Court.
MedCity News
JUNE 27, 2024
While it it’s too early to judge the success of Kaiser Permanente’s Risant Health, the company’s first two acquisitions show a commitment to adjoining organizations with a strong focus on population health — as well as a dedication to spreading Kaiser’s value-based care delivery models across the country. The post What Do Experts Make of Risant Health’s Newest Acquisition?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JUNE 27, 2024
With Regeneron’s treatment delayed, AbbVie is expanding its T-cell engager competition against Roche in blood cancer with a new FDA approval. | With Regeneron's treatment delayed, AbbVie is expanding its T-cell engager competition against Roche in blood cancer with a new FDA approval.
MedCity News
JUNE 27, 2024
Verona Pharma’s COPD drug Ohtuvayre is a single small molecule that blocks two targets to bring patients both bronchodilation and anti-inflammatory effects. Verona executives contend their inhalable drug has key advantages over the last novel COPD medication, the orally administered roflumilast. The post Verona Pharma Drug With Dual Mechanism Lands FDA Approval in COPD appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
JUNE 27, 2024
The FDA rejected Daiichi Sankyo and Merck's HER3 antibody-drug conjugate. Novo Nordisk's weight loss star Wegovy secured approval in China. | The FDA rejected Daiichi Sankyo and Merck's HER3 antibody-drug conjugate. Novo Nordisk's weight-loss star Wegovy secured approval in China. After two large licensing deals, Takeda's CEO is open to more partnerships with Chinese biotechs.
PharmaVoice
JUNE 27, 2024
Neuroscience pipelines are reawakening as biotechs prove to the pharma giants that the field is still worth the investment.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
JUNE 27, 2024
Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster.The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years, according to Verona.
Pharmaceutical Technology
JUNE 27, 2024
Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.
pharmaphorum
JUNE 27, 2024
SCOTUS rejects bankruptcy deal that would settle opioid litigation against Purdue Pharma, but also protect the Sackler family from liability.
Pharmaceutical Technology
JUNE 27, 2024
Formation Bio has secured $372m in Series D funding to bolster its drug pipeline and expand its AI-driven drug development platform.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Clarivate
JUNE 27, 2024
Discover how our combination of data-driven insights and analysis in digital health research and innovation highlight global societal impact in our latest report Digital health encompasses the use of digital technologies such as mobile apps, wearables and telemedicine, to improve health and healthcare delivery. The digital health landscape is evolving rapidly.
Pharmaceutical Technology
JUNE 27, 2024
US-based 2seventy bio has completed an asset purchase agreement (APA) to divest its haemophilia A candidate to Novo Nordisk.
MedCity News
JUNE 27, 2024
GI disorders are complex, disruptive, and immensely stressful, with physiological, psychological, and sociological implications. The post The Impact of GI Disorders on Women’s Mental Health appeared first on MedCity News.
Pharmaceutical Technology
JUNE 27, 2024
NovoNordisk acquired the hypertension and kidney disease drug ocedurenone from KBP Biosciences in 2023 as part of a $1.3bn deal.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
JUNE 27, 2024
It is crucial that we preserve the unique public-private partnership framework that drives innovation in our country by ensuring that the Bayh-Dole Act remains intact. The post Biden’s ‘March-In-Rights’ Proposal Undermines 40-Year-Old Policy, and Endangers Life-Saving Innovation appeared first on MedCity News.
pharmaphorum
JUNE 27, 2024
FDA rejects MSD, Daiichi Sankyo’s HER3-targeted ADC patritumab deruxtecan because of problems at a third-party manufacturer
Pharmaceutical Commerce
JUNE 27, 2024
The deal offers member pharmacies two pricing options, which will take effect Aug. 1.
pharmaphorum
JUNE 27, 2024
CSL Behring's gene therapy Hemgenix for haemophilia B has been backed for reimbursement in England and Denmark.
Quantified
JUNE 27, 2024
Introduction In the ever shifting landscape of sales, enablement is crucial for business success. Sales enablement provides sales teams with the tools, resources, and information they need to engage buyers and close deals effectively. However, several pain points can hinder these efforts. Leveraging artificial intelligence (AI) can significantly mitigate these challenges, transforming sales enablement into a more efficient and effective process.
European Pharmaceutical Review
JUNE 27, 2024
Considering recent EU and US approvals, there has been a continued trend of exciting innovative therapies reaching market, demonstrating promise for a range of hard-to-treat-diseases. In May and June, regulatory approvals have so far included treatments for rare disorders as well as in oncology, such as blood, endometrial and colorectal cancers. Looking back briefly to 2023, within the cell and gene therapy space, the US Food and Drug Administration (FDA) approved marketing authorisations for se
pharmaphorum
JUNE 27, 2024
FDA reveals diversity action plan guide for clinical trials Phil.
Pharmaceutical Commerce
JUNE 27, 2024
The latest news for pharma industry insiders.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmaTech
JUNE 27, 2024
Fruzaqla was previously approved for use in patients with metastatic colorectal cancer in the US in November 2023.
PharmExec
JUNE 27, 2024
The Complete Response Letter was issued as a result of inspection findings at a third-party manufacturing facility, unrelated to patritumab deruxtecan’s efficacy or safety in patients with advanced or metastatic EGFR-mutated non-small cell lung cancer.
PharmaTech
JUNE 27, 2024
This $4.1 billion investment to build a second fill/finish manufacturing facility in Clayton, N.C., boosts Novo Nordisk's current 2024 investments in production to $6.8 billion.
PharmExec
JUNE 27, 2024
Approval of Epkinly was based on results from the Phase I/II EPCORE trial in patients with relapsed or refractory follicular lymphoma who have already completed two or more lines of systemic therapy.
Pharmaceutical Commerce
JUNE 27, 2024
A longitudinal observational study examined whether the program was related to access to hospital-based services, while determining if that association differs by hospital ownership.
Scott Burrows
JUNE 27, 2024
In the fast-paced world of financial services, where each day presents fresh challenges and intense competition, I stand as a beacon of inspiration and expert guidance. My journey of resilience and triumph empowers financial service organizations and their teams to cultivate a belief system that conquers any obstacle while embracing change. Through compelling storytelling and practical insights, I vividly illustrate how enduring principles such as Vision, Mindset, and Grit lead to remarkable ach
PharmExec
JUNE 27, 2024
In an interview with Pharm Exec Associated Editor Don Tracy, Leonard Mazur, Co-Founder, CEO, Citius Pharmaceuticals, discusses recent topline results from the pivotal Phase III Clinical Trial of Mino-Lok, which works to salvage catheters infections.
PharmaTech
JUNE 27, 2024
No timetable was given for the length of the planned evaluation or when data would be available, but Kite intends to use the information to expand its manufacturing options.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
266 
Let's personalize your content